Skip to content

sublingual Alprazolam spray in panic attacks

Preparation and comparison of the efficacy of sublingual Alprazolam spray with oral tablets in reducing the duration and intensity of panic attacks: A clinical trial study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250929067414N1
Enrollment
86
Registered
2025-12-22
Start date
2025-12-28
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Attack. Acute stress reaction

Interventions

Intervention 1: Intervention group: Sublingual alprazolam spray. Intervention 2: Intervention group: alprazolam tab.

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Male and female patients diagnosed with panic attacks aged between 18 and 65 years. Patients who have been diagnosed with panic disorder based on DSM-5 criteria No change in treatment regimen in the last 4 months. Full consent to participate in the study. Having at least basic literacy skills.

Exclusion criteria

Exclusion criteria: Previous use of alprazolam or other benzodiazepines in the past month. Liver disease Kidney disease. Pregnancy and breastfeeding. History of seizures History of asthma History of allergy to benzodiazepines. History of addiction to benzodiazepines, alcohol, or drugs. Patients receiving strong 3A4 inhibitors.

Design outcomes

Primary

MeasureTime frame
The improvement of the intensity and duration of panic attacks using the score obtained from the Body Sensation Questionnaire. Timepoint: At the beginning of the study and after each panic attack until the end of three months. Method of measurement: Body Sensation Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa panahishokouh

Esfahan University of Medical Sciences

mahsapanahishokooh@gmail.com+98 31 3792 4170

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026